A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer

Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Study ID
NCT07711184
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • HRS-7525 tablets — DRUG
    HRS-7525 tablets

Study Details

The purpose of this study is to evaluate the safety and tolerability of HRS-7525 in participants with Advanced Prostate Cancer, and to determine the dose limiting toxicity (DLT), the maximum tolerated dose (MTD, if possible), and the recommended Phase II dose (RP2D) of HRS-7525.

Key Dates

First listed
Jul 17, 2026
Start date
Jul 31, 2026
Status verified
Jul 2026
Primary completion
Jun 30, 2028
Completion
Dec 31, 2029

Study Design

Enrollment
320 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: HRS-7525 tablets

Primary Outcome Measure

dose limiting toxicity (DLT) [ Time Frame: a single-dose run-in period (2 days) and 21 days after the first administration of each subject ]

Central Contacts

Find similar trials

Nationwide
Prostate cancer trialsOncology trialsProstate oncology trialsMen's health trialsUrology trials

Related Studies